Chiasma, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases. Its product candidate is octreotide capsules or MYCAPSSA, which has completed Phase III clinical trial for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massachusetts.
thestreet.com - Chiasma's Acromegaly Drug Headed for FDA Rejection, Investor Says Chiasma (CHMA) is expecting the U.S. Food and Drug Administration to make an approval decision Friday on a new oral treatment for acromegaly, a rare disease of the pituitary gland. One of my most reliable (and bearish) investor sources believes the FDA will reject the Chiasma capsules, known as Mycapssa, because data from the company's pivotal, single-arm study failed to demonstrate a clinically meaningful benefit for acromegaly patients.
FDA rejected the drug, and trading is halted. CHMA will issue a response on Monday. http://finance.yahoo.com/news/u-fda-rejects-chiasmas-drug-225321231.html
